Research programme: monoclonal antibodies - Aridis Pharmaceuticals

Drug Profile

Research programme: monoclonal antibodies - Aridis Pharmaceuticals

Alternative Names: Anti-infective mAbs - Kenta Biotech/Aridis; AR 201 (anti-RSV mAb) - Aridis; AR 401 (anti-AB mAb) - Aridis; AR-201; AR-401; KBAB 401; KBPA 102; KBPA 103; KBPA 104; KBRV 201; KBSA 201; KBSA 302

Latest Information Update: 26 Feb 2016

Price : $50

At a glance

  • Originator Kenta Biotech
  • Developer Aridis Pharmaceuticals; Kenta Biotech
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acinetobacter infections; Pneumonia; Pseudomonal infections; Respiratory syncytial virus infections; Staphylococcal infections

Most Recent Events

  • 24 Feb 2016 Aridis Pharmaceuticals has patent protection for AR 401 in USA and Europe
  • 13 Oct 2015 Aridis Pharmaceuticals receives SBIR grant from the National Institutes of Health
  • 15 May 2013 Aridis Pharmaceuticals acquires Kenta Biotech's entire portfolio of anti-infective monoclonal antibodies, including panobacumab and AR 301
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top